Although no consensus was made about how much a marker must add to clinical models in terms of discrimination and reclassification improvements, this study demonstrated some supporting evidence of TSG-6 in non-cardioembolic AIS diagnosis and the value of prognosis assessment and provided a potential target for non-cardioembolic AIS treatment. The gene discussed is TNFAIP6; the disease is androgen insensitivity syndrome.